Search results

...'''cangrelor''' is an [[purinergic P2Y receptor antagonist]]s that is a [[platelet aggregation inhibitor]]. ...Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW et al.| title=Effect of platelet inhibition with cangrelor during PCI on ischemic events. | journal=N Engl J

{{r|Platelet}}

{{r|Platelet transfusion}}

...antagonize or impair any mechanism leading to blood [[platelet activation|platelet aggregation]], whether during the phases of activation and shape change or Inhibitors of the [[platelet glycoprotein GPIIb-IIIa complex]] (GPIs) include the [[monoclonal antibody]

{{r|Platelet}}

{{r|Platelet}}

==Anatomy of a platelet== ...brand factor]]), the contents of which are released upon activation of the platelet. These granule contents play an important role in both [[hemostasis]] and i

...nce of [[fibrin]] strands following the mixing of plasma with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of t

...nism of [[phagocytosis]]. They produce [[leukotriene]] C₄ and [[platelet activation factor]] (PAF). <ref name=Ganong>{{citation ...Ganong, p. 508</ref> Especially infectious parasites produce inhibitors of platelet aggregation.<ref name=Liu>{{citation

...of [[hematoepoesis]]: generation of [[erythrocyte]]s, [[leukocyte]]s and [[platelet]]s from [[hematopoetic stem cell]]s.

{{r|Platelet||**}}

{{r|Platelet-derived growth factor receptor||**}}

...nthase]] by acetylating its terminal amino group. Aspirin also inhibits [[platelet]] aggregation and is used in the prevention of arterial and venous [[thromb Individuals in whom platelet function assays demonstrate resistance to aspirin are less likely to have c

...s]] include [[leukocyte]]s for immune and infection-fighting action, and [[platelet]]s for clotting.

...eptor]]s, and [[purinoceptor P2Y12|purinoceptor P2Y₁₂]] (causes platelet aggregation).

*[[Platelet]]s per unit volume

...ansduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway."<ref>{{MeSH}}</ref>

...('''TTP''') is "an acquired, congenital, or familial disorder caused by [[platelet aggregation]] with [[thrombosis]] in terminal arterioles and capillaries. C

...hich leads to profound low [[white blood cell]], [[red blood cell]], and [[platelet]] counts.

...does not irreversibly inhibit [[cyclooxygenase]] and thus is not an [[anti-platelet agent]].

...ess bleeding, particularly since the patient has typically been given anti-platelet medications during the procedure. The duration of anti-platelet therapy is uncertain.<ref name="pmid20231231">{{cite journal| author=Park S

...chemicals, especially [[histamine]]. They also release [[leukotriene]]s, [[platelet aggregation factor]], [[eosinophil chemotactic factor]]-A, and a [[basophi

* Pohl's Index is if the AST/ALT ratio ≥1 and platelet count ≤ 150,000/mm³ then cirrhosis is very likely.<ref name="p ...307/8/832/F3.expansion.html Bonacini score] is based on the ALT/AST ratio, platelet count, and INR.<ref name="pmid16437635">{{cite journal| author=Colli A, Col

...al vasculature, [[brain]] || [[vasoconstriction]], [[gluconeogenesis]], [[platelet]] aggregation, and release of [[factor VIII]] and [[von Willebrand factor]]

Elevations in [[platelet]]s and [[lactic dehydrogenase]] also can artificially raise the potassium l

| Primary NSTEMI: Nonocclusive grayish-white thrombus<br/>(platelet-rich)<br/> ...2738"/> NSTEMI is usually caused by a grayish-white [[thrombus]] that is [[platelet]]-rich.<ref name="pmid1728732">{{cite journal |author=Mizuno K, Satomura K,

...ng and clotting times. Large volumes decrease hematocrit, plasma proteins, platelet counts, and hemoglobin.

...f the three types of blood cells: [[erythrocytes]]s, [[leukocyte]]s and [[platelet]]s. Although not a true [[neoplasia|malignant neoplasm]], MDS is neverthel * [[Thrombocytopenia]] (low platelet count)—increased susceptibility to [[bleeding]]

...le=Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with

|Smooth muscle, basophils, mast cells, [[platelet]]s, [[eosinophil]]s

...educes the risk of [[hemorrhage]], they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also

...messenger that triggers a step toward the creation of [[leukocyte]]s or [[platelet]]s from the original [[pluripotent stem cell]]s. GM-CSF actually operates

...age:Red White Blood cells.jpg|thumb|From left to right: [[erythrocyte]], [[Platelet|thrombocyte]], [[leukocyte]].]] ...4,000&ndash;11,000 [[white blood cells]] and about 150,000&ndash;400,000 [[platelet]]s in a cubic millimeter of human blood. The red blood cells store collecti

* [[Platelet count]]

*Moreover, exposure to cigarette smoke results in [[platelets|platelet]] activation, stimulation of the coagulation cascade, and impairment of ant

...maximum dose of Zevalin is 32 mCi. For previously untreated NHL, however, platelet counts must be a minimum of 150,000/m³ and treatment must begin

...o [[blood component transfusion]] such as [[erythrocyte transfusion]] or [[platelet transfusion]].

Coagulation, along with [[platelet activation]], leads to [[hemostasis]]. ...n due to a variety of factors such as coagulation protein disorders; blood platelet disorders; blood protein disorders or nutritional conditions."<ref name="Me

...358">{{cite journal| author=Beyan C, Kaptan K, Beyan E, Turan M| title=The platelet count/mean corpuscular hemoglobin ratio distinguishes combined iron and vit

...lume= 20 | issue= 6 | pages= 603-10 | pmid=11075846 }} </ref>|| "The lower platelet 5-HT during treatment with [[citalopram]] than amitriptyline indicates that

| Nonocclusive grayish-white thrombus<br/>(platelet-rich) | Primary NSTEMI: Nonocclusive grayish-white thrombus<br/>(platelet-rich)<br/>

...asting 2–7 days; 2) positive tourniquet test or spontaneous bleeding; 3) [[platelet]] count 100x10⁹/L or less; 4) plasma leakage shown either by hem

...of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammat

* Platelet dysfunction

* [[Platelet aggregation inhibitors]] and other anti-hemostatic agents according to [[me

In [[medicine]], '''clopidogrel''' is a [[thienopyridine]] class [[platelet aggregation inhibitor]]. It is used in the [[secondary prevention]] of [[st

...ase in 1996, however, the victim experienced severe hemolysis and complete platelet destruction after which the liver and kidneys began to fail. When it was fe

...*2 [[allele]] may reduce the occurrence of patients with high on-treatment platelet reactivity.<ref name="pmid22464343">{{cite journal| author=Roberts JD, Well

===Anti-platelet drugs=== The most effective anti-platelet treatment is probably to combine aspirin, 25 mg twice a day with extended-r

...sion properties. Studies have shown that addition of PAF or inhibition of platelet-activating factor acetylhydrolase (PAF-AH) decreases cerebellar granule cel